Microbiome Therapeutic Market

Global Market Study on Microbiome Therapeutics: United States Projected to be the Dominant Regional Market During 2018 - 2025

  • January-2018
  • PMRREP7990
  • 144 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Human microbiome to have a tremendous impact on human health

Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.

Destructive changes in the human microbiome composition, called as dysbiosis, is considered as a key factor in allergies, arthritis, asthma, autism, colon cancer, C. difficile infections, diabetes, inflammatory bowel disease, obesity and many other diseases. Currently there are no approved microbiome therapeutics available in the market and it will take a couple of years more work on candidates currently in pipeline and launch them in the market.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to surpass US$ 890 Mn by 2025 end, exhibiting an exponential CAGR of 62.9% over 2018–2025. At present there are no marketed microbiome therapeutics in the global market, however, the first drug is expected to be launched in 2018.

Targeting micriobime for correction of dysbiosis is emerging as a therapeutic option for many indications including diabetes, autoimmune disorders, oncology, obesity, rate diseases, gynaecological and neonatal disorders, bacterial infections, urinary tract infections etc. among others.

Find Out More about the Report Coverage

Companies

Company Profiles

  • Microbiome Therapeutics Inc.
  • SERES Therapeutics Inc.
  • LNC Therapeutics Inc.
  • Vedanta Biosciences Inc.
  • Enterome SA
  • Ferring B.V.
  • ViThera Pharmaceuticals Inc.
  • Second Genome Therapeutics
  • Rebiotix
  • Synlogic Inc.
  • 4D Pharma Plc.
  • Ritter Pharmaceuticals
  • AvidBiotics
  • Osel Inc.
  • OxThera AB
  • Evelo Biosciences
  • AOBiome LLC
  • Immuron Ltd.

Improved microbiome sequencing capabilities are likely to boost the global microbiome therapeutics market

Results from the Human Microbiome Project and other massive studies of human bacterial symbioses have drawn enormous attention from applied biomedical research organizations, which is the primary factor expected to driving the growth of global microbiome therapeutics market. Human Microbiome Project (HMP) has led to identification of 60 Mn genes, 600 microbial reference genome and sequencing of 700 metagenomes, whereas MetaHIT catalogue contains 3.3 Mn non-redundant human microbiome genes in almost every set of genes for human gut microbiome. All of this information is being used to translate microbiome science to therapeutics. Another important factor expected to speed up growth of global microbiome therapeutics market is improved microbiome sequencing capabilities. This, in turn, is expected to boost the basic research in microbiome sequencing and reveal more about diversity of microbiome, which can be applied to discover new or improved microbiome therapeutics.

Huge pipeline of microbiome therapeutics with over 120 candidates in development would decide the future of microbiome therapeutics market. However, lack of clear regulatory pathways and delays in launch of microbiome therapeutics are major factors expected to hamper the growth of microbiome therapeutics market.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Global microbiome therapeutics market study, by indication

Based on indication, the global microbiome therapeutics market has been segmented into

  • Type 2 diabetes
  • Obesity
  • C. difficile Infection
  • Primary hyperoxyurea

C. difficile infection indication segment is expected to contribute highest share of over 34% by 2025. This high share is expected to be due to early launch and more number of launches of C. difficile microbiome therapeutics in the market.

Some of the other indications for which active microbiome therapeutics clinical trials are going on include gastrointestinal disorders (Crohn's disease, inflammatory bowel diseases, ulcerative colitis), prevention of preterm birth, immuno-oncology, rare metabolic disorders such as phenylketonuria, urea cycle disorders, lactose intolerance, glioblastoma etc. 

global microbiome therapeutics market

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Global microbiome therapeutics market study, by region

Global market for microbiome therapeutics is segmented into four key regions viz. U.S., Europe, Japan and Rest of the world (RoW). U.S. is expected to contribute highest market share of over 44% by 2025 in global microbiome therapeutics market. Early launch of new drugs in the U.S. and rapid penetration is expected to drive the growth of the U.S. microbiome therapeutics market.

Explore Persistence Market Research’s expertise in promulgation of the business !

Market Taxonomy

By Indication

  • Type 2 Diabetes
  • Obesity
  • difficile infection
  • Primary Hyperoxyurea

 By Region

  • U.S.
  • Europe
  • Japan
  • RoW

Media Release

Our Clients

Our Clients